Company expects to resubmit revised toxicology package to MHRA by end of Q3 2026
Traws Pharma aims to resolve FDA clinical hold and advance U.S. program by end of 2026
Company projects existing cash will fund operations into Q1 2027; may need more financing after
Overview
US biopharmaceutical firm's Q2 revenue fell to zero from prior yr due to licensing termination
Net loss for Q2 widened yr/yr, driven by higher general and administrative expenses
Company completed April 2026 private placement, enabling access to up to $50 mln in financing
Result Drivers
Revenue decline - Co attributed lack of Q2 revenue to non-recurring deferred revenue recognized in prior yr from terminated oncology licensing agreement
R&D spending drop - Q2 R&D expenses fell yr/yr due to lower spending on tivoxavir marboxil program
Higher G&A costs - Q2 G&A expenses rose yr/yr due to higher professional and consulting fees and increased stock-based compensation
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Traws Pharma Inc is $1.00, about 66.7% above its August 13 closing price of $0.60
TRAW•
